CTLA4 and neoplasm: Additionally, there may be clinical differences between patients who received anti-PD1 monotherapy and those treated with the anti-PD1-CTLA-4 combination therapy, particularly in terms of tumour burden, prognostic factors, and treatment decisions, which could have influenced the frequency of HPD.